Effects of Strength Exercise on Fall Risk in Elderly With Alzheimer's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Andalucía
-
Jaén, Andalucía, Spain
- A.F.A La Estrella
-
-
Madrid
-
Alcalá De Henares, Madrid, Spain, 28805
- Alexander achalandabaso
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- accept to participate in the study, through informed consent
- subjects aged 60 or over with medical diagnosis of Azlheimer´s disease
- minimal physical and mental state to perform the cognitive tests and strength exercise routine
Exclusion Criteria:
- Neurodegenerative disease other than Alzheimer's disease
- Suffering from serious somatic or psychiatric illnesses
- Patients who have practiced strength exercise regularly
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention group
This is the group that receives strength exercise in addition to usual treatment
|
Strength exercise protocol for upper and lower limbs, using weights and elastic bands
The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
|
|
Other: Control group
This is the group that only receives usual treatment
|
The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Short physical performance battery (SPPB) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
Informs about fall risk and mobility Score: 0-12 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Activities specific balance confidence scale (ABC scale) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This questionnaire allows to measure the balance of a person Score: 0-100% High percentage means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Lawton Instrumental Activities of Daily Living Scale (IADL) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This tool gives us information about performance in activities of daily living Score: 0-8 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Quality of life Alzheimer Disease (QoL-AD) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
Through this test we can know the level of quality of life of users who suffer from this disease Score: 0-52 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline FRAIL test at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This rapid test allows to determine the state of frailty of older people Score: 0-5 High score means worst result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Mini Mental State Examination (MMSE) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This test gives us information about the cognitive performance of the participants Score: 0-30 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Neuropsychiatric Inventory (NPI-Q) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This tool allows to specify the neuropsychiatric symptoms patients present Score: 0-36 High score means worst result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Manual dynamometry at 1,2,3 and 6 months
Time Frame: Baseline, 1, 2, 3 and 6 months (3 months after intervention)
|
This test allows to quantify force an individual presents in a simple way Score: 0-∞ High score means better result
|
Baseline, 1, 2, 3 and 6 months (3 months after intervention)
|
|
Modified Borg scale
Time Frame: 3 times/week during strength exercises sessions
|
In this way we can measure the level of perceived exertion during the intervention with strength exercise Score: 0-10 High score means more fatigue
|
3 times/week during strength exercises sessions
|
|
Change from baseline One Maximum repetition strength test (1 MR) at 1,2,3 and 6 months
Time Frame: Baseline, 1 , 2 , 3 and 6 months (3 months after intervention)
|
Allows you easily to assess maximum strength Score: 0-∞ High score means more strength level
|
Baseline, 1 , 2 , 3 and 6 months (3 months after intervention)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CEIH/FEB.21/8.TES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.